Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$36.31
−$0.08 · -0.22%
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Previous close
$36.31
−$0.08 · -0.22%
Regular session · ET · Market data may be delayed.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Day range
Current $36.31
52-week range
Current $36.31
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
54
Fair Value
Sentiment
71
Bullish
Risk
20
Low Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Day range
Current $36.31
52-week range
Current $36.31
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 726.41M USD | 700.97M USD | 674.98M USD | 666.82M USD | 541.53M USD |
| Cost of goods sold | 149.75M USD | 170.43M USD | 184.67M USD | 199.3M USD | 140.26M USD |
| Gross profit | 576.66M USD | 530.54M USD | 490.31M USD | 467.53M USD | 401.28M USD |
| Research and development | 117.31M USD | 81.58M USD | 76.26M USD | 84.8M USD | 55.55M USD |
| Selling, general, and administrative | 368.76M USD | 294.1M USD | 269.44M USD | 254.52M USD | 199.35M USD |
| Operating expenses | 543.36M USD | 603.91M USD | 402.63M USD | 407.5M USD | 311.35M USD |
| Interest income | 22.73M USD | 19.69M USD | 11.44M USD | 4.54M USD | 896K USD |
| Interest expense | 14.61M USD | 16.57M USD | 17.31M USD | 35.58M USD | 29M USD |
| Depreciation and amortization | 91.02M USD | 78.79M USD | 75.57M USD | 91.5M USD | 28.55M USD |
| Operating income | 33.3M USD | −73.37M USD | 87.68M USD | 60.02M USD | 89.92M USD |
| Net income | 7.03M USD | −99.56M USD | 41.96M USD | 15.91M USD | 41.98M USD |
Company facts updated Oct 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$31.67
12.78% downsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR86.6M0.08%103.19B USD0.06%$137.55+0.17%
iShares Russell 2000 ETFIWM37.88M0.05%78.74B USD0.19%$278.94+0.49%
Avantis U.S. Small Cap Value ETFAVUV34.42M0.11%30.85B USD0.25%$119.64-0.41%
Vanguard Morningstar Total Stock Market ETFVTI31.05M0.00%2.3T USD0.03%$381.94+0.63%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV29.21M0.11%26.81B USD0.33%$37.95-0.39%
Vanguard Morningstar Small-Cap ETFVB22.23M0.01%185.3B USD0.03%$289.48+0.64%
Dimensional - US Targeted Value ETFDFAT14.99M0.05%30.12B USD0.33%$67.27-0.43%
Vanguard Morningstar Small-Cap Value ETFVBR14.14M0.02%68.2B USD0.05%$234.43+0.22%iShares Core S&P Small-Cap ETFIJRiShares Russell 2000 ETFIWMAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIU.S. Small Cap Value Portfolio ETF Class SharesDFSVVanguard Morningstar Small-Cap ETFVBDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Value ETFVBRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
